Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):338-40. doi: 10.1097/QAI.0000000000000598.

Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.

Author information

1
*Southwest CARE Center, Santa Fe, NM; †Inst. Dominicano de Estudios Virologicos, Santo Domingo, Dominican Republic; ‡HIV Unit, Hospital Civil de Guadalajara, Guadalajara, Mexico; §Department of Medicine, Khonkaen University, Khonkaen, Thailand; ‖Orlando Immunology Center, Orlando, FL; ¶Instituto de Saúde Ambiental, Faculdade de Medicina de Lisboa, Lisbon, Portugal; #EPIMED, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; **Infectious Diseases Department, "Luigi Sacco" Hospital, Milan, Italy; ††Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; and ‡‡Gilead Sciences, Inc., Foster City, CA.

Abstract

BACKGROUND:

Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.

METHODS:

International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.

RESULTS:

At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.

CONCLUSIONS:

Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

PMID:
26181707
DOI:
10.1097/QAI.0000000000000598
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center